Write your message
Volume 5, Issue 4 (Fall 2020)                   J Obstet Gynecol Cancer Res 2020, 5(4): 137-148 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Rahimi M, Keyhani E, Behjati F. The Relation between Exon Variations of KIT Gene and Clinical Pathological Factors of Breast Cancer. J Obstet Gynecol Cancer Res. 2020; 5 (4) :137-148
URL: http://jogcr.com/article-1-297-en.html
1- Department of Microbiology, Karaj Branch, Islamic Azad University, Karaj, Iran , mar.rahimi20@gmail.com
2- Genetics Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran
Abstract:   (102 Views)

Background & Objective:  As the most common cancer type, breast cancer has been recognized as the second mortality cause among women. The KIT proto-oncogene is one of the important factors involved in tumor development. The previous findings have demonstrated an increased copy number and overexpression of this gene under the influence of breast cancer development.
Materials & Methods: This study aimed to investigate the relationship between the copy number variation (CNV) of all exons of KIT gene and estrogen receptor (ER), progesterone receptor (PR), HER2, P53, stage, tumor size, Ki67, Annexin V, histological type, age, molecular subtype, and node status by surveying breast cancer tissues collected from 64 patients. The CNV exons and clinicopathological variables were assessed by multiplex ligation-dependent probe amplification (MLPA), hematoxylin and eosin (H&E) staining, and immunohistochemistry techniques.
Results: Sixty percent of cases in exon 17, 60% in exon 18, and nearly 67% in exon 19 with increased CNVs had a tumor size of 2-5 cm; these results were significant. Also, patients with an increased exon 7 CNV were significantly in stage 3. Other exons did not exhibit significant relation to other clinicopathological variables (P>0.05).
Conclusion:   Exons 7, 17, 18, and 19 are the key coding domains of tyrosine kinase, involving the activation of various upstream transcription factors that regulate apoptosis, cell differentiation, proliferation, and angiogenesis. Variation in exons can influence drug resistance. The results of this study can contribute to the diagnosis and treatment of breast cancer, although their confirmation requires further examinations.

Full-Text [PDF 723 kb]   (36 Downloads)    
Systematic Review: Original Research | Subject: Gynecology Oncology
Received: 2020/06/8 | Accepted: 2020/08/20 | Published: 2020/09/8

References
1. Miettinen M, Lasota J. KIT (CD117): A Review on Expression in Normal and Neoplastic Tissues, and Mutations and Their Clinicopathologic Correlation.Appl Immunohistochem Mol Morphol 2005;13: 205-220 [DOI:10.1097/01.pai.0000173054.83414.22] [PMID]
2. Ribatti D, Nico B, Crivellato E, Roccaro AM, Vacca A. The history of angiogenic switch concept. Leukemia.2007; 21(1): 44-52. [DOI:10.1038/sj.leu.2404402] [PMID]
3. Fakhrejahani E, Toi M. Antiangiogenesis Therapy for Breast Cancer: An Update and Perspectives from Clinical Trials. Jpn J Clin Oncol. 2014; 44(3): 197-207 [DOI:10.1093/jjco/hyt201] [PMID] [PMCID]
4. Tuveson D, Willis N, Jacks T, Gri J, Singer S. STI571 inactivation of the gastrointestinal stromal tumor c-KIToncoprotein: biological and clinical implications. Oncogene.2001; 20:5054-58. [DOI:10.1038/sj.onc.1204704] [PMID]
5. Orsenigo M, Brich S, Riva C, Conca E, Bertulli R, Dileo P, Gronchi A, Casali PG, Pierotti MA, Tamborini E, Pilotti S. Fluorescence in situ hybridization analysis and immunophenotyping of c-Kit/PDGFRA and Bcl-2 expression in gastrointestinal stromal tumors. Anal Quant CytolHistol. 2010;32 (4):225-33.
6. Lasota J, Miettinen M, Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Histopathology.2008; 53(3):245-266. [DOI:10.1111/j.1365-2559.2008.02977.x] [PMID]
7. Malaise M, Steinbach D, Corbacioglu S, Clinical implications of c-Kit mutations in acute myelogenous leukemia. Find out how to access preview-only content. Current Hematologic Malignancy Reports. 2009; 4(2): 77-82. [DOI:10.1007/s11899-009-0011-8] [PMID]
8. Renneville A, Roumier C, Biggio V, Nibourel O, Boissel N, Fenaux P, Preudhomme C. Cooperating gene mutations in acute myeloid leukemia: a review of the literature. Leukemia 2008; 22:915-931. [DOI:10.1038/leu.2008.19] [PMID]
9. Beadling C, Jacobson-Dunlop E, Hodi FS, Le C, Warrick A, Patterson J, Town A, Harlow A. KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res. 2008;14 (21):6821-8. [DOI:10.1158/1078-0432.CCR-08-0575] [PMID]
10. Lee JY, Park K, Lim S H, Kim H S, Yoo K H, Jung K S, Song H, Hong M. Mutational profiling of brain metastasis from breast cancer: matched pair analysis of targeted sequencing between brain metastasis and primary breast cancer.Oncotarget. 2015; 22; 6(41):43731-42. [DOI:10.18632/oncotarget.6192] [PMID] [PMCID]
11. Judith A. Gilbert, Matthew P. Goetz, Carol A. Reynolds, James N. Ingle, Karin F.Giordano. Molecular analysis of metaplastic breast carcinoma. Mol Cancer Ther. 2008; 7(4): 944-951 [DOI:10.1158/1535-7163.MCT-07-0570] [PMID] [PMCID]
12. Kondi-Pafiti A, Arkadopoulos N, Gennatas C, Michalaki V, Frangou-Plegmenou M. Expression of c-kit in common benign and malignant breast lesions. Tumori. 2010; 96: 978-984 [DOI:10.1177/548.6519] [PMID]
13. Johansson I, E. Aaltonen K, Ebbesson A, Grabau D, Wigerup C, Hedenfalk I, Increased Gene Copy Number of KIT and VEGFR2 at4q12 in Primary Breast Cancer is Related to an Aggressive Phenotype and Impaired Prognosis GENES.CHROMOSOMES & CANCER.2012; 51:375-383 [DOI:10.1002/gcc.21922] [PMID]
14. Jansson S, Grabau D, Falck A, Aaltonen K. The Three Receptor Tyrosine Kinases c-KIT, VEGFR2 and PDGFRa, Closely Spaced at 4q12, Show Increased Protein Expression in Triple-Negative Breast Cancer. PLOS ONE.2014; 9 (7):102176. [DOI:10.1371/journal.pone.0102176] [PMID] [PMCID]
15. Liu J, Liu X, Feng X, Liu J, Lv S, Zhang W, Niu Y. C-kit overexpression correlates with KIT gene copy numbers increases in phyllodes tumors of the breast. Breast Cancer Res Treat. 2014; 149 (2):395-401. [DOI:10.1007/s10549-014-3214-1] [PMID]
16. Zhu Y, Wang Y, Guan B, Rao Q, Wang J, Ma H, Zhang Z, Zhou X. C-kit and PDGFRA gene mutations in triple negative breast cancer.Int J ClinExpPathol. 2014;7(7):4280-4285.
17. Rahimi M , Behjati F, Khorram Khorshid HR , Karimlou M, Keyhani E. The Relationship between KIT Copy Number Variation, Protein Expression, and Angiogenesis in Sporadic Breast Cancer. Reports of Biochemistry & Molecular Biology. 2020; 9(1): 40-49. [DOI:10.29252/rbmb.9.1.40] [PMID] [PMCID]
18. Rahimi M , Behjati F,Taheri, N, Hosseini S, Khorram Khorshid HR, Moghaddam F. Correlation between Important Genes of mTOR Pathway (PI3K and KIT) in Iranian Women with Sporadic Breast Cancer. Med J Islam Repub Iran. 2018; 32.135. [DOI:10.14196/mjiri.32.135] [PMID] [PMCID]
19. Kitamura Y, Hirota S. Kit as a human oncogenic tyrosine kinase. Cell Mol Life Sci. 2004; 61:2924-2931. [DOI:10.1007/s00018-004-4273-y] [PMID]
20. Miettinen M, Lasota J. Gastrointestinal stromal tumors: definition, occurrence, pathology, differential diagnosis and molecular genetics. Pol J Pathol. 2003; 54:3-24.
21. Carvalho S, Silva A, Milanezi F, Ricardo S, Leita D, Amendoeira I, Schmitt FC. c-KIT and PDGFRA in breast phyllodes tumours:Over expression without mutations? ClinPathol. 2004; 57: 1075-1079. [DOI:10.1136/jcp.2004.016378] [PMID] [PMCID]
22. Tan PH, Jayabaskar T, Yip G, et al. p53 and c-kit (CD117) protein expression as prognostic indicators in breast phyllodes tumors: a tissue microarray study. Mod Pathol. 2005;18(12):1527-1534. [DOI:10.1038/modpathol.3800488] [PMID]
23. Lux ML, Rubin BP, Biase TL, Chen CJ, Maclure T, Demetri G, Xiao S, Singer S, Fletcher CD and Fletcher JA. KIT extracellular and kinase do¬main mutations in gastrointestinal stromal tu¬mors. Am J Pathol 2000; 156: 791-795. [DOI:10.1016/S0002-9440(10)64946-2]
24. Dy GK, Miller AA, Mandrekar SJ, Aubry MC, Langdon RM Jr, Morton RF, Schild SE, Jett JR and Adjei AA. A phase II trial of imatinib (ST1571) in patients with c-kit expressing re¬lapsed small-cell lung cancer: a CALGB and NCCTG study. Ann Oncol 2005; 16: 1811-1816. [DOI:10.1093/annonc/mdi365] [PMID]
25. Antonescu C, Romeo S, Zhang L, Nafa K,.Hornick J, Nielsen G, Mino-Kenudson M, Huang H, Mosquera J, Dei Tos P, Fletcher. C. Dedifferentiation in Gastrointestinal Stromal Tumor to an Anaplastic KIT Negative Phenotype - a Diagnostic Pitfall. Morphologic and Molecular Characterization of 8 Cases Occurring either de-novo or after Imatinib Therapy.Am J SurgPathol. 2013; 37(3): 385-392. [DOI:10.1097/PAS.0b013e31826c1761] [PMID] [PMCID]
26. Reichardt P, Hogendoorn PC, Tamborini E, Loda M, Gronchi A, Poveda A et al, Gastrointestinal stromal tumors I: pathology, pathobiology, primary therapy, and surgical issues.Semin Oncol.2009; 36(4):290-301. [DOI:10.1053/j.seminoncol.2009.06.002] [PMID]
27. Martin-Broto J, Rubio L, Alemany R, Lopez-Guerrero JA, Clinical implications of KIT and PDGFRA genotyping in GIST. Clin Trans Oncol.2010; 12(10):670-676. [DOI:10.1007/s12094-010-0576-7] [PMID]
28. Zhao F, Chen Y, Wu Q, Wang Z, Lu J, Prognostic value of CD117 in cancer: a metanalysis. Int J Clin Exp Pathol 2014;7(3):1012-1021.
29. Babaei M A, Kamalidehghan B, Saleem M, Huri H Z, Ahmadipour F, Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells. Drug Des Devel Ther. 2016; 10: 2443-2459. [DOI:10.2147/DDDT.S89114] [PMID] [PMCID]
30. LU H Y, ZHANG G,CHENG Q, CHEN B, CAI J, WANG X, ZHANG Y, WANG Z, LU Z, XIE F, MAO W, Expression and mutation of the c-kit gene and correlation with prognosis of small cell lung cancer. Oncol Lett. 2012; 4(1): 89-93. [DOI:10.3892/ol.2012.679] [PMID] [PMCID]
31. Ahmed R, Din H U, Akhtar F, Afzal S, Muhammad I, Hashmi S N, Immunohistochemical Expression of Epidermal Growth Factor Receptor and c-Kit in Triple Negative Breast Cancer. Journal of the College of Physicians and Surgeons Pakistan 2016;26 (7): 570-572.
32. Natali PG, Nicotra MR, Sures I. Expression of c-kit receptor in normal and transformed human nonlymphoid tissues. Cancer Res. 1992; 52:6139-6143.
33. Matsuda R, Takahashi T, Nakamura S. Expression of the c-kit protein in human solid tumors and in corresponding fetal and adult normal tissues. Am J Pathol. 1993;142:339-346.
34. Lasota J. Not all c-kit mutations can be cor¬rected by imatinib. Lab Invest 2007; 87: 317. [DOI:10.1038/labinvest.3700538]
35. Atay S, Banskota S, Crow J , Sethi G. Oncogenic KIT-containing exosomes increase gastrointestinal stromal tumor cell invasion. PNAS, 2014. 111 (2) 711-716. [DOI:10.1073/pnas.1310501111] [PMID] [PMCID]
36. McIntyre A, Summersgill B, Grygalewicz B, Gillis AJ, Stoop J, van Gurp RJ, Dennis N, Fisher C, Huddart R, Cooper C, Clark J, Oosterhuis JW, Looijenga LH, Shipley J. Amplification and overexpression of the KIT gene is associated with progression in the seminoma subtype of testicular germ cell tumors of adolescents and adults. Cancer Res. 2005; 65 (18): 8085-9. [DOI:10.1158/0008-5472.CAN-05-0471] [PMID]

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


© 2021 All Rights Reserved | Journal of Obstetrics, Gynecology and Cancer Research (JOGCR)

Designed & Developed by : Yektaweb | Piblisher: Farname Inc.